Ratio of free-PSA/total-PSA: An indicator for differentation between patients with prostate cancer and benign prostatic hyperplasia;Das verhältnis freies PSA/gesamt-PSA - Eine kenngröße zur differenzierung zwischen patienten mit prostatakarzinom und benigner prostatahyperplasie: Welcher diskriminationspunkt sollte gewählt werden?

Aktuelle Urologie

Volumn 28, Issue 6, 1997, Pages 323-328

  Lein, M ^a,b   Stephan, C ^a   Jung, K ^a   Koenig, F ^a   Schnorr, D ^a   Loening, S A ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Discrimination limits; Free psa; Prostate cancer; Prostate specific antigen

Indexed keywords

EID: 0031527234     PISSN: 00017868     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1054297     Document Type: Article

References (48)

1. Armbruster, D. A.: Prostate-specific antigen: biochemistry, analytical methods, and clinical application [Review]. Clin. Chem. 39 (1993) 181-195
2. Belanger, A., H. Vanhalbeek, H. C. B. Graves, K. Grandbois, T. A. Stamey, L. H. Huang: Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. Prostate 27 (1995) 187-197
3. Bjartell, A., T. Björk, M. T. Matikainen, P. A. Abrahamsson. A. di Sant'Agnese, H. Lilja: Production of alpha-1-antichymotrypsin by PSA-containing cells of the human prostate epithelium. Urology 42 (1993) 502-510
4. Björk, T., S. Hulkko, A. Bjartell, A. di Sant'Agnese, P. A. Abrahamsson, H. Lilja: Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology 43 (1994) 427-434
5. Blijenberg, B. G., I. Eman, E. R. Boeve, E. Mössner, W. Uhl: The analytical and clinical performance of the new Boehringer Mannheim Enzymun-test PSA assay for prostate-specific antigen. Eur. J. Clin. Chem. Clin. Biochem. 33 (1995) 383-392
6. Bostwick, D. G.: Prostate-specific antigen. Current role in diagnostic pathology of prostate cancer. Am. J. Clin. Pathol. 102 (1994) 31-37
7. Bunting, P. S.: A guide to the interpretation of serum prostate specific antigen levels. Clin. Biochem. 28 (1995) 221-241
8. Catalona, W. J., J. W. Colberg, D. S. Smith, et al.: Measurement of percent-free PSA improves specificity for lower PSA cut-offs in prostate cancer screening. J. Urol. (Suppl) 155 (1996) 422A
9. Catalona, W. J., M. A. Hudson, P. T. Scardino, J. P. Richie, F. R. Ahmann, R. C. Flanigan: Selection of optimal prostate specific antigen cut-offs for early detection of prostate cancer: receiver operating characteristic curves. J. Urol. 152 (1994) 2037-2042
10. Catalona, W. J., D. S. Smith: Comparison of different serum prostate specific antigen measures for early prostate cancer detection. Cancer 74 (1994) 1516-1518
11. Catalona, W. J., D. S. Smith, D. K. Ornstein: Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 277 (1997) 1452-1455
12. Catalona, W. J., D. S. Smith, R. L. Wolfert, T. J. Wang, H. G. Rittenhouse, T. L. Ratliff, R. B. Nadler: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274 (1995) 1214-1220
13. Chen, Z. X., A. Prestigiacomo, T. A. Stamey: Purification and characterization of prostate-specific antigen (PSA) complexed to alpha(1)-antichymotrypsin: potential reference material for international standardization of PSA immunoassays. Clin. Chem. 41 (1995) 1273-1282
14. Christensson, A., T. Björk, O. Nilsson, U. Dahlen, M. T. Matikainen, A. T. K. Cockett: Serum prostate specific antigen complexed to alpha(1)-antichymotrypsin as an indicator of prostate cancer. J. Urol. 150 (1993) 100-105
15. Christensson, A., C. B. Laurell, H. Lilja: Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur. J. Biochem. 194 (1990) 755-763
16. Demura, T., N. Shinohara, M. Tanaka, et al.: The proportion of free to total prostate specific antigen. Cancer 77 (1996) 1137-1143
17. 1-antichymotrypsin (PSA/ACT) and uncomplexed PSA in serum from patients with benign prostate hypertrophy (BPH) and prostate cancer (PCA) using dual monoclonal assay. J. Urol. 49 [Suppl] (1993) 333A
18. Elgamal, A., F. Cornillie, W. Van der Poppel, et al.: Free/total PSA ratio as a single test for detection of significant T1c prostate cancer. J. Urol. [Suppl] 155 (1996) 369A
19. th International Hamburg Symposium on Tumor Markers, Anticancer Res. 15 (1995) 2400
20. Filella, X., J. Alcover, R. Molina, et al.: Clinical usefulness of free PSA fraction as an indicator prostate cancer. Int. J. Cancer 63 (1995) 780-784
21. th International Hamburg Symposium on Tumor Markers, Anticancer Res. 15 (1995) 2396
22. 1-antichymotrypsin. Prostate 27 (1995) 166-175
23. Jacobsen, S. J., J. E. Oesterling: Age-specific reference ranges for serum prostate specific antigen levels. J. Clin. Ligand. Assay 18 (1995) 93-97
24. Jung, K., M. Lein, D. Schnorr, W. Henke, B. Brux, S. A. Loening: Prostataspezifisches Antigen (PSA): Einfluß des freien und gebundenen Anteils auf die klinische Aussagekraft als Tumormarker. Lab. Med. 19 (1995) 210-217
25. Jung, K., C. Stephan, M. Lein, W. Henke, D. Schnorr, B. Brux, P. Schürenkämper, S. A. Loening: Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin. Chem. 42 (1996) 1026-1033
26. Lilja, H.: Regulation of the enzymatic activity of prostate-specific antigen and its reactions with cellular protease inhibitors in prostate cancer. Scand. J. Clin. Lab. Invest. 55 [Suppl 220] (1995) 47-56
27. 1-antichymotrypsin. Clin. Chem. 37 (1991) 1618-1625
28. Luderer, A. A., Y. T. Chen, T. F. Soriano, et al.: Measurement of the proportion of free to total prostate-specific antigen improves diagnostic gray zone of total prostate-specific antigen. Urology 46 (1995) 187-194
29. Milford Ward, A., K. Green, R. Wilford: Free/total PSA ratio as an aid to the diagnosis of prostate carcinoma. Clin. Chem. 41 (1995) 230
30. Mitrunen, K., K. Pettersson, T. Piironen, T. Björk, H. Lilja, T. Lövgren: Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin. Chem. 41 (1995) 1115-1120
31. Morgan, T. O., D. McLeod, J. W. Moul, et al.: Clinical use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA. J. Urol. [Suppl] 155 (1996) 370A
32. Morote, J., C. X. Raventos, J. A. Lorente, et al.: Measurement of free PSA in the diagnosis and staging of prostate cancer. Int. J. Cancer 71 (1997) 756-759
33. Oesterling, J. E., S. J. Jacobsen, G. G. Klee, K. Pettersson, T. Piironen, P. A. Abrahamsson: Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J. Urol. 154 (1995) 1090-1095
34. Oesterling, J. E., G. L. Wojno, A. Vashi, et al.: Determination of the "Reflex Range" and appropriate cutpoints for % free PSA in 413 men referred for prostate evaluation using the AxSym System. J. Urol. [Suppl] 155 (1996) 370A
35. Passing, H., W. Bablok: A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry. Part I. J. Clin. Chem. Clin. Biochem. 21 (1983) 709-720
36. th International Hamburg Symposium on Tumor Markers. Anticancer Res. 15 (1995) 2402
37. Pettersson, K., T. Piironen, M. Seppälä, L. Liukkonen, A. Christensson, M. T. Matikainen: Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha(1)-antichymotrypsin complex. Clin. Chem. 41 (1995) 1480-1488
38. Prestigiacomo, A., T. A. Stamey: Clinical usefulness of free and complexed PSA. Scand. J. Clin. Lab. Invest. 55 [Suppl 221] (1995) 32-34
39. th International Hamburg Symposium on Tumor Markers. Anticancer Res. 15 (1995) 2396
40. Reissigl, A., H., Klocker, J. Pointer, et al.: Usefulness of the ratio free/ total prostate-specific antigen in addition to total PSA levels in prostate cancer screening. Urology 48 (1996) 62-66
41. Semjonow, A., B. Brandt, F. Oberpennig, et al.: Unterschiedliche Bestimmungsverfahren erschweren die Interpretation des prostataspezifischen Antigens. Urologe (A) 34 (1995) 303-315
42. th International Hamburg Symposium on Tumor Markers. Anticancer Res. 15 (1995) 2397
43. Stamey, T. A., A. F. Prestigiacomo, Z. Chen: Standardization of immunoassays for prostate specific antigen: a different view based on experimental observations. Cancer 74 (1994) 1662-1666
44. Stenman, U. H., J. Leinonen, H. Alfthan, et al.: A complex between prostate-specific antigen and arantichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 51 (1991) 222-226
45. th International Hamburg Symposium on Tumor Markers. Anticancer Res. 15 (1995) 2400
46. Uhl, W., E. Mössner: Evaluation of free PSA in the Enzym-Test format. In: Schnorr, D., S. A. Loening, S. Dinges (eds.): Locally advanced prostate cancer T3/C. Blackwell-Verlag, Berlin, 1995, p 270
47. Van Cangh, P. J., P. Denayer, P. Sauvage, et al.: Clinical value of free/ total prostate specific antigen ratio: data from 453 histologically confirmed prostate tumors. Urol. J. Urol. 155 (Suppl) (1996) 534A
48. Zweig, M. H., G. Campbell: Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine [Review]. Clin. Chem. 39 (1993) 561-577